Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review
Therapeutic cancer vaccines aim to generate a robust immune response against tumour-associated antigens (TAAs) or tumour-specific antigens. While their safety is well established, their efficacy as monotherapy remains limited due to factors such as self-tolerance to TAAs and the immunosuppressive tu...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-02-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359251316988 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849765873883021312 |
|---|---|
| author | Igor Gomez-Randulfe Helen Lavender Stefan Symeonides Fiona Blackhall |
| author_facet | Igor Gomez-Randulfe Helen Lavender Stefan Symeonides Fiona Blackhall |
| author_sort | Igor Gomez-Randulfe |
| collection | DOAJ |
| description | Therapeutic cancer vaccines aim to generate a robust immune response against tumour-associated antigens (TAAs) or tumour-specific antigens. While their safety is well established, their efficacy as monotherapy remains limited due to factors such as self-tolerance to TAAs and the immunosuppressive tumour microenvironment. Combining cancer vaccines with systemic anticancer therapies (SACTs) offers a promising strategy to improve efficacy. However, the optimal timing and combination with immune checkpoint inhibitors (ICIs) and chemotherapy to enhance immunogenicity are not yet fully understood. This review aims to assess the evidence regarding the immunogenicity of antiviral and anticancer vaccines when combined with SACTs, including chemotherapy and ICIs, with a particular focus on the timing of vaccine administration relative to SACT. Additionally, we evaluate the impact of steroids on immunogenicity. Our findings suggest that the timing of vaccine administration is critical, with improved immunogenic responses observed when vaccines are administered at nadir (15 days post-chemotherapy). Certain chemotherapies, such as low-dose metronomic cyclophosphamide and paclitaxel, demonstrate potential for immunomodulation, enhancing T-cell responses when combined with vaccines. Conversely, steroids may reduce immunogenicity. The combination of ICIs with cancer vaccines shows evidence of a synergistic effect, with concurrent administration generally yielding better outcomes than sequential approaches. Prospective trials exploring various timings and sequences are essential to optimize the efficacy of anticancer vaccines. |
| format | Article |
| id | doaj-art-3252279e12fd4e08af7d2bf9ec53b9ec |
| institution | DOAJ |
| issn | 1758-8359 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj-art-3252279e12fd4e08af7d2bf9ec53b9ec2025-08-20T03:04:44ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592025-02-011710.1177/17588359251316988Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a reviewIgor Gomez-RandulfeHelen LavenderStefan SymeonidesFiona BlackhallTherapeutic cancer vaccines aim to generate a robust immune response against tumour-associated antigens (TAAs) or tumour-specific antigens. While their safety is well established, their efficacy as monotherapy remains limited due to factors such as self-tolerance to TAAs and the immunosuppressive tumour microenvironment. Combining cancer vaccines with systemic anticancer therapies (SACTs) offers a promising strategy to improve efficacy. However, the optimal timing and combination with immune checkpoint inhibitors (ICIs) and chemotherapy to enhance immunogenicity are not yet fully understood. This review aims to assess the evidence regarding the immunogenicity of antiviral and anticancer vaccines when combined with SACTs, including chemotherapy and ICIs, with a particular focus on the timing of vaccine administration relative to SACT. Additionally, we evaluate the impact of steroids on immunogenicity. Our findings suggest that the timing of vaccine administration is critical, with improved immunogenic responses observed when vaccines are administered at nadir (15 days post-chemotherapy). Certain chemotherapies, such as low-dose metronomic cyclophosphamide and paclitaxel, demonstrate potential for immunomodulation, enhancing T-cell responses when combined with vaccines. Conversely, steroids may reduce immunogenicity. The combination of ICIs with cancer vaccines shows evidence of a synergistic effect, with concurrent administration generally yielding better outcomes than sequential approaches. Prospective trials exploring various timings and sequences are essential to optimize the efficacy of anticancer vaccines.https://doi.org/10.1177/17588359251316988 |
| spellingShingle | Igor Gomez-Randulfe Helen Lavender Stefan Symeonides Fiona Blackhall Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review Therapeutic Advances in Medical Oncology |
| title | Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review |
| title_full | Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review |
| title_fullStr | Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review |
| title_full_unstemmed | Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review |
| title_short | Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review |
| title_sort | impact of systemic anticancer therapy timing on cancer vaccine immunogenicity a review |
| url | https://doi.org/10.1177/17588359251316988 |
| work_keys_str_mv | AT igorgomezrandulfe impactofsystemicanticancertherapytimingoncancervaccineimmunogenicityareview AT helenlavender impactofsystemicanticancertherapytimingoncancervaccineimmunogenicityareview AT stefansymeonides impactofsystemicanticancertherapytimingoncancervaccineimmunogenicityareview AT fionablackhall impactofsystemicanticancertherapytimingoncancervaccineimmunogenicityareview |